Ranibizumab Ophthalmic

DRUG4 trials

Sponsors

Retina Macula Institute, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's, Universidad Autonoma de San Luis Potosí, Parc de Salut Mar

Conditions

Diabetic Macular EdemaEye DiseasesNeovascular Age Related Macular DegenerationPremature BirthRetinal DiseaseRetinopathy of Prematurity Both EyesWet Age-related Macular Degeneration

Phase 2

Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration

CompletedNCT00764738

Retina Macula InstituteNeovascular Age Related Macular Degeneration

Start: 2008-10-31End: 2011-11-30Updated: 2020-09-22

Phase 3

Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)

RecruitingNCT06952452

Parc de Salut MarWet Age-related Macular Degeneration

Start: 2022-11-18End: 2026-07-31Target: 630Updated: 2025-11-20

Phase 4

VEGF Concentrations After Intravitreal Bevacizumab vs Ranibizumab as a Treatment for Type 1 ROP

CompletedNCT03148132

Universidad Autonoma de San Luis PotosíEye Diseases, Premature Birth, Retinal Disease +1

Start: 2017-05-23End: 2018-08-30Updated: 2019-01-09

Unknown Phase

Changes to the Retina Following Anti-VEGF Treatments for Diabetic Macular Edema

CompletedNCT02979665

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sDiabetic Macular Edema

Start: 2014-09-30End: 2017-08-31Updated: 2019-05-02